Primary Outcomes:

Primary Outcome 1 - Measure: Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

Primary Outcome 1 - Time Frame: Initiation of study treatment through 100 days post-last dose (up to approximately 27 months)

Primary Outcome 2 - Measure: Objective Response Rate (ORR) in Phase 2 using RECIST v1.1

Primary Outcome 2 - Time Frame: Initiation of study treatment until disease progression (up to approximately 27 months)

Primary Outcome 3 - Measure: Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902

Primary Outcome 3 - Time Frame: Up to approximately 6 months

Condition:

• Non Small Cell Lung Cancer
• Colorectal Cancer
• Gastroesophageal Adenocarcinoma
• Urothelial Carcinoma

Eligibility

Criteria:
Inclusion Criteria:

- Provide a signed and dated informed consent form prior to initiation of study-specific
procedures.

- Patients with the indicated advanced or metastatic solid tumor as follows:

1. NSCLC who are planned for or have received no more than 1 cycle of systemic
treatment with cytotoxic, platinum-based chemotherapy

2. GEA who are planned for or have received no more than 1 cycle of systemic
treatment with cytotoxic, platinum-based chemotherapy

3. mUC who are planned for or have received no more than 1 cycle of systemic
treatment with cytotoxic, platinum-based chemotherapy

4. CRC-MSS who are receiving first line systemic therapy or who are planned for or
have received no more than 1 cycle of second line systemic therapy including a
fluoropyrimidine and oxaliplatin or irinotecan

- 18 years of age or older

- ECOG Performance Status 0 or 1

- Lesion amenable to biopsy

- Measurable disease according to RECIST v1.1

- Have adequate organ function, as measured by laboratory values (criteria listed in
protocol)

Exclusion Criteria:

- Tumors with genetic characteristics as follows:

1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1,
RET, or TRK

2. For CRC and GEA, patients with MSI disease

3. For CRC, patients with a known BRAF V600E mutation or patients with peritoneal
carcinomatosis

- Patients with known central nervous system (CNS) metastases and/or carcinomatous
meningitis

- Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to a
vaccination

- Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significant
bruising or bleeding following IM injections or blood draws

Complete inclusion and exclusion criteria are listed in the clinical study protocol.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No